Search

everythinglearnresearchcommunity

for

Search:↓

A female user's diagnosis of androgenetic alopecia, and the advice shared in response which suggests taking spironolactone and minoxidil together to prevent hair loss.

A 39-year-old user has been using topical 0.3% finasteride with 6% minoxidil for almost 7 months without seeing significant improvement in hair regrowth. They are considering switching to a gel with higher minoxidil concentration, adding retinoic acid, or trying topical dutasteride, while others suggest returning to 5% minoxidil foam, adding oral finasteride, or exploring microneedling and lifestyle changes.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

The user experienced severe side effects from finasteride and switched to using minoxidil and a derma stamp, seeing positive hair regrowth after initial shedding. They are considering topical finasteride to avoid side effects while maintaining hair health.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

RU58841 users discuss seeing results in a few months. Minoxidil and finasteride are also mentioned as treatments.

User on 1mg finasteride and 5% minoxidil for 7 weeks sees some progress. Others suggest adding dutasteride and microneedling.

Balding can be traumatic for many, affecting self-esteem and social interactions, while others accept it more easily. Treatments mentioned include finasteride, minoxidil, and RU58841.

Hairline progress after one year using 5mg oral minoxidil and 0.5mg dutasteride daily. Some users struggle to see the difference, but overall discussion includes treatment experience and age.

A user discusses making DIY dutasteride capsules from powder bought from China, using a mix of MCT oil and propylene glycol. Others warn about the risks of incorrect dosing, potential degradation, and the possibility of receiving fake products.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation humorously speculates that bald Grey Aliens might be future humans who haven't solved baldness, despite advanced technology. Treatments like microneedling, minoxidil, and finasteride are mentioned as potential solutions.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

User doubts oral minoxidil's effectiveness after a month of use and shedding. Few people provide photo evidence of success, and some combine it with other treatments, making it hard to determine its effectiveness alone.

Minoxidil may cause facial aging or wrinkles, though opinions vary. Some users report side effects like dark circles and facial bloating, while others attribute changes to genetics or other factors.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A user in Egypt is seeking alternatives to oral minoxidil, which is banned there, after stopping topical minoxidil due to concerns for their cat's safety. Suggestions include drinking diluted topical minoxidil or making homemade minoxidil tablets, but these methods carry significant risks and are not recommended.

A user from France is seeking ways to obtain oral minoxidil in the EU without a prescription, as local doctors are hesitant to prescribe it. Suggestions include visiting Spain for a prescription, ordering online, or consulting doctors in other EU countries like Portugal.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.